Genentech, PeptiDream ink potential $1B radiopharma deal
Published: Sep 20, 2023
By Kate Goodwin
The latest deal builds on previous partnerships between the two companies starting in December 2015 with licensing in 2016 and an expansion deal in 2018.
PeptiDream will receive $40 million upfront for R&D of its macrocyclic peptide-radioisotope drug conjugates. Going forward, another $1 billion is on the line in milestones plus tiered royalties of product sales to markets outside of Japan. PeptiDream will oversee preclinical activities to develop a peptide-RI drug conjugate and retain rights in Japan for any products developed.
While a particular target was not disclosed, PeptiDream CEO Patrick Reid said in a statement that the company hopes to “bring innovative first-in-class peptide radiopharmaceuticals to patients worldwide.”
The peptide-RI drug conjugates in the deal with Genentech are designed to use radioisotopes to hit a cancer cell directly, minimizing off-target toxicity. The biopharma’s Peptide Discovery Platform System is designed to identify a range of candidates for peptide-based, small molecule-based or peptide drug conjugates-based therapeutics.
BMS has two oncology assets that are partnered with PeptiDream. One is a PD-L1 inhibitor peptide and the other is a radiopharmaceutical diagnostic agent to evaluate PD-1/PD-L1 expression in patients. Both are currently in Phase I testing.
In March 2023, PeptiDream announced a second targeted peptide radiopharmaceutical candidate has been nominated for clinical development in its partnership with RayzeBio. The first candidate is indicated for liver cancer, a disease with a market size estimated at $5.3 billion by 2029 in the eight major markets, according to PeptiDream.